Danazol in treatment of lupus thrombocytopenia.
Seven patients with systemic lupus erythematosus (SLE), persistent thrombocytopenia (TP), in whom it was considered undesirable to institute an increase in steroid or immunosuppressive agents, were treated with danazol. Five patients completed the minimum period of 8 weeks. Two patients showed early response to danazol but were switched over to cyclophosphamide or azathioprine after 4 weeks because of systemic disease. Of the remaining five patients, four had complete responses. In one patient who failed treatment the TP was considered to be related to another drug (ranitidine). Other manifestations of SLE also improved with treatment. Side effects included amenorrhea in one patient, and hypoglycemia and hyponatremia in another. Infections were absent. Danazol can be a useful alternative treatment of lupus TP.
Wong
K L
KL
Department of Medicine, Queen Mary Hospital, Hong Kong.
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets; D003613:Danazol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D011899:Ranitidine / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000188:drug therapy*
D011899:Ranitidine; D003613:Danazol